Company Filing History:
Years Active: 2014
Title: Marian Grade: Innovator in Cancer Research
Introduction
Marian Grade is a notable inventor based in Goettingen, Germany. He has made significant contributions to the field of cancer research, particularly in understanding the responsiveness of rectal adenocarcinomas to treatment.
Latest Patents
Marian Grade holds a patent for a composition that detects the response of rectal adenocarcinomas to radiochemotherapy. This innovative patent utilizes a cDNA array consisting of 9984 genes for expression profiling in rectal adenocarcinoma. The expression data obtained from this array were correlated with the responsiveness to chemotherapy followed by radiotherapy. Through this research, a set of 54 genes was identified as being differentially expressed in responders versus non-responders. These genes may serve as prognostic markers to determine whether a rectal adenocarcinoma is responsive to radiochemotherapy.
Career Highlights
Marian Grade is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to focus on groundbreaking research that has the potential to improve treatment outcomes for patients with rectal adenocarcinoma.
Collaborations
Some of his notable coworkers include Thomas Ried and Michael J Difilippantonio. Their collaborative efforts contribute to the advancement of cancer research and the development of innovative treatment strategies.
Conclusion
Marian Grade's work in cancer research exemplifies the impact of innovation in medical science. His patent on the detection of treatment responsiveness in rectal adenocarcinomas highlights the importance of genetic profiling in improving patient care.